I agree with you. Their estimate beat far outweighs the solvaldi price issue. Gilead is extremely undervalued at its current price. The government simply wanted an explanation; It's not like they completely halted the sale of the drug. Oh and btw Gilead DID mention the solvaldi price issue at their conference call at 4:15 today:
"The value of a cure, I tend to think, is underestimated in terms of the overall advantage that the health care system receives from it," Chief Operating Officer John Milligan said in Tuesday's conference call, detailing the long-term cost of treating patients with hepatitis C against the short-term cost of Gilead's drug regimen.
Market Data 
Markets 
AI
